GILEAD SCIENCES INC

NASDAQ: GILD (Gilead Sciences, Inc.)

最近更新时间: 12 Jul, 1:09AM

109.64

-4.90 (-4.28%)

  • 1天 -4.28%
  • 5天 -1.89%
  • 1月 1.05%
  • 6月 17.94%
  • 今年至今天 19.33%
  • 1年 51.42%
  • 5年 40.42%
前收盘价格 114.54
收盘价格 113.75
成交量 6,104,993
平均成交量 (3个月) 8,463,060
市值 136,384,479,232
市盈率 (P/E TTM) 23.03
预期市盈率 (P/E Forward) 14.12
价格/销量 (P/S) 4.89
股市价格/股市净资产 (P/B) 7.26
52周波幅
70.21 (-35%) — 119.96 (9%)
利润日期 7 Aug 2025
股息率 (DY TTM) 2.85%
营业毛利率 20.76%
营业利益率 (TTM) 38.49%
稀释每股收益 (EPS TTM) 4.73
季度收入增长率 (YOY) -0.30%
季度盈利增长率 (YOY) 24.80%
总债务/股东权益 (D/E MRQ) 130.79%
流动比率 (MRQ) 1.37
营业现金流 (OCF TTM) 10.37 B
杠杆自由现金流 (LFCF TTM) 9.99 B
资产报酬率 (ROA TTM) 12.14%
股东权益报酬率 (ROE TTM) 32.65%

市场趋势

短期 中期
行业 Drug Manufacturers - General (US) 混合的 混合的
Drug Manufacturers - General (全球的) 混合的 混合的
股票 Gilead Sciences, Inc. 看涨 看涨

AIStockmoo 评分

1.1
分析师共识 4.0
内部交易活动 -1.5
价格波动 -0.5
技术平均移动指标 2.5
技术振荡指标 1.0
平均 1.10

相关股票

股票 市值 DY P/E（TTM） P/B
GILD 136 B 2.85% 23.03 7.26
AMGN 160 B 3.11% 27.16 25.34
AZN 226 B 2.13% 29.27 5.37
SNY 118 B 4.58% 16.37 1.35
GRFS 6 B - 28.00 0.960
BIIB 20 B - 13.29 1.16

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
部门 Healthcare
行业 Drug Manufacturers - General
投资方式 Large Value
内部持股比例 0.10%
机构持股比例 89.60%
52周波幅
70.21 (-35%) — 119.96 (9%)
目标价格波幅
125.00 (14%) — 135.00 (23%)
高 135.00 (Morgan Stanley, 23.13%) 购买
中 125.00 (14.01%)
低 125.00 (Oppenheimer, 14.01%) 购买
125.00 (Cantor Fitzgerald, 14.01%) 购买
平均值 128.33 (17.05%)
总计 3 购买
平均价格@调整类型 103.95
公司 日期 目标价格 调整类型 价格@调整类型
Morgan Stanley 25 Apr 2025 135.00 (23.13%) 购买 103.17
Oppenheimer 25 Apr 2025 125.00 (14.01%) 购买 103.17
Cantor Fitzgerald 22 Apr 2025 125.00 (14.01%) 购买 105.51

该时间范围内无数据。

  • 3M
日期 类型 细节
14 Jul 2025 公告 Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for HIV Prevention at IAS 2025
09 Jul 2025 公告 Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
25 Jun 2025 公告 Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
18 Jun 2025 CNBC FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option
18 Jun 2025 公告 Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
17 Jun 2025 CNBC Targeted cancer drugs may replace chemo for some patients — and drugmakers say they're getting closer
01 Jun 2025 公告 Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
31 May 2025 公告 Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer
23 May 2025 公告 ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast Cancer Who Are Not Candidates for Checkpoint Inhibitors
15 May 2025 公告 Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
12 May 2025 CNBC Trump's plan to slash drug prices may struggle to get off the ground – here's what to know 
07 May 2025 公告 Gilead’s Livdelzi® (Seladelpar) Demonstrated Consistent Efficacy and Safety Regardless of Prior Treatment History in New Data Presented at EASL 2025
07 May 2025 公告 Final Data From the Phase 3 MYR301 Study Demonstrated Longer Treatment With Bulevirtide Was Associated With Sustaining Undetectability After Stopping Treatment
29 Apr 2025 公告 Gilead Sciences to Present at Upcoming Investor Conferences
29 Apr 2025 公告 Gilead to Present Latest Advancements Across Primary Biliary Cholangitis and Viral Hepatitis
28 Apr 2025 公告 Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
24 Apr 2025 公告 Gilead Sciences Announces First Quarter 2025 Financial Results
24 Apr 2025 CNBC Corporate America shelled out millions for Trump's inauguration. Now he's upending many of their businesses
21 Apr 2025 公告 Trodelvy® Plus Keytruda® Demonstrates a Statistically Significant and Clinically Meaningful Improvement in Progression Free Survival in Patients With Previously Untreated PD-L1+ Metastatic Triple-Negative Breast Cancer
显示更多
股息率 (DY TTM) 2.85%
5年平均股息收益率 3.80%
股息支付比率 65.13%
预计下次股息支付 Sep 2025
除息日 公告日期 支付日期 详情
13 Jun 2025 22 Apr 2025 27 Jun 2025 0.79 现金
14 Mar 2025 05 Feb 2025 28 Mar 2025 0.79 现金
13 Dec 2024 30 Oct 2024 30 Dec 2024 0.77 现金
13 Sep 2024 30 Jul 2024 27 Sep 2024 0.77 现金
14 Jun 2024 23 Apr 2024 27 Jun 2024 0.77 现金
14 Mar 2024 01 Feb 2024 28 Mar 2024 0.77 现金
14 Dec 2023 01 Nov 2023 28 Dec 2023 0.75 现金
14 Sep 2023 25 Jul 2023 28 Sep 2023 0.75 现金
14 Jun 2023 25 Apr 2023 29 Jun 2023 0.75 现金
14 Mar 2023 25 Jan 2023 30 Mar 2023 0.75 现金
14 Dec 2022 25 Oct 2022 29 Dec 2022 0.73 现金
14 Sep 2022 25 Jul 2022 29 Sep 2022 0.73 现金
14 Jun 2022 27 Apr 2022 29 Jun 2022 0.73 现金
14 Mar 2022 28 Jan 2022 30 Mar 2022 0.73 现金
14 Dec 2021 26 Oct 2021 30 Dec 2021 0.71 现金
14 Sep 2021 26 Jul 2021 29 Sep 2021 0.71 现金
14 Jun 2021 27 Apr 2021 29 Jun 2021 0.71 现金
12 Mar 2021 02 Feb 2021 30 Mar 2021 0.71 现金
14 Dec 2020 26 Oct 2020 30 Dec 2020 0.68 现金
14 Sep 2020 29 Jul 2020 29 Sep 2020 0.68 现金
11 Jun 2020 29 Apr 2020 29 Jun 2020 0.68 现金
12 Mar 2020 03 Feb 2020 30 Mar 2020 0.68 现金
12 Dec 2019 23 Oct 2019 30 Dec 2019 0.63 现金
12 Sep 2019 29 Jul 2019 27 Sep 2019 0.63 现金
13 Jun 2019 01 May 2019 27 Jun 2019 0.63 现金
14 Mar 2019 01 Feb 2019 28 Mar 2019 0.63 现金
13 Dec 2018 24 Oct 2018 28 Dec 2018 0.57 现金
13 Sep 2018 24 Jul 2018 27 Sep 2018 0.57 现金
14 Jun 2018 30 Apr 2018 28 Jun 2018 0.57 现金
15 Mar 2018 05 Feb 2018 29 Mar 2018 0.57 现金
14 Dec 2017 25 Oct 2017 28 Dec 2017 0.52 现金
14 Sep 2017 25 Jul 2017 28 Sep 2017 0.52 现金
14 Jun 2017 01 May 2017 29 Jun 2017 0.52 现金
14 Mar 2017 06 Feb 2017 30 Mar 2017 0.52 现金
13 Dec 2016 31 Oct 2016 29 Dec 2016 0.47 现金
14 Sep 2016 22 Jul 2016 29 Sep 2016 0.47 现金
14 Jun 2016 27 Apr 2016 29 Jun 2016 0.47 现金
14 Mar 2016 02 Feb 2016 30 Mar 2016 0.43 现金
14 Dec 2015 26 Oct 2015 30 Dec 2015 0.43 现金
14 Sep 2015 23 Jul 2015 29 Sep 2015 0.43 现金
12 Jun 2015 24 Apr 2015 29 Jun 2015 0.43 现金
显示更多

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2025 1.58 2 1.44
2024 3.08 4 3.33
2023 3.00 4 3.70
2022 2.92 4 3.40
2021 2.84 4 3.91
2020 2.72 4 4.67
2019 2.52 4 3.88
2018 2.28 4 3.65
2017 2.08 4 2.90
2016 1.84 4 2.57
2015 1.29 3 1.28
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票